Spots Global Cancer Trial Database for Application of 68Ga-Pentixafor PET/CT for Thymoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Application of 68Ga-Pentixafor PET/CT for Thymoma
Official Title: Chemokine Receptor CXCR4-targeting PET Imaging for Thymoma
Study ID: NCT06086327
Conditions
Interventions
Study Description
Brief Summary: Chemokine receptor CXCR4 was expressed in T cells and CXCR4-targeting molecular imaging- 68Ga-Pentixafor PET/CT could be a promising technique to evaluate the extent of thymoma with higher accuracy. This prospective study is going to investigate whether metabolic characterization by 68Ga-Pentixafor PET/CT may be superior for diagnosis, distinguish evaluation for thymoma.
Detailed Description: Thymoma is 1 rare type of tumor developed on the thymic epithelium; patients with thymoma also might have myasthenia gravis (MG). Because of the scarcity and complexity of MG-associated thymoma, its pathogenesis and etiology still remain unclear nowadays. The expression of C-X-C chemokine receptor type 4 (CXCR4) is absent or low in most healthy tissues but highly expressed in various types of tumors. CXCR4 might contribute to the clinical cancer progression, and CXCR4 could be a valuable prognostic biomarker in the therapy of MG-associated thymoma.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Peking Union Medical College Hospitall, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, Beijing, China
Contact Details
Name: Zhaohui Zhu
Affiliation: Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
